PMID: 9549661Apr 29, 1998Paper

Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans

Journal of Clinical Pharmacology
M T MarinoK C Lasseter

Abstract

This study was conducted to determine the pharmacokinetics and pharmacodynamics of pyridostigmine given as 30 mg of pyridostigmine bromide every 8 hours in healthy subjects. Plasma pyridostigmine concentration and red blood cell acetylcholinesterase activity were measured in blood samples collected during a 3-week period. Population analysis was performed using standard pharmacokinetic and pharmacodynamic models with the nonlinear mixed-effect modeling software (NONMEM). The pharmacokinetic model that best fit the pyridostigmine plasma levels was a two-compartment open model with first-order absorption, a lag time, and first-order elimination from the central compartment. The pharmacodynamic model that best fit red blood cell acetylcholinesterase activity was an inhibitory Emax model with an effect compartment linked to the central compartment. The results showed that the pharmacokinetics of pyridostigmine bromide are both gender and weight dependent. The pharmacodynamic effect does not lag significantly from the plasma concentration and returns to near normal within 8 hours. With the present dosage regimen of 30 mg every 8 hours, 30% of individuals may not have red blood cell acetylcholinesterase inhibition > 10% at the time o...Continue Reading

References

Jan 1, 1978·Toxicology and Applied Pharmacology·J J GordonM P Maidment
Sep 1, 1989·The Journal of Pharmacy and Pharmacology·R I Ellin, A Kaminskis
May 1, 1985·Clinical Pharmacology and Therapeutics·U Breyer-PfaffF Schumm
May 1, 1972·Clinical Pharmacology and Therapeutics·S M SomaniA Wilson
Feb 1, 1974·Toxicology and Applied Pharmacology·F R Sidell, W A Groff
Jul 1, 1980·Clinical Pharmacology and Therapeutics·R CronnellyL B Sheiner
Oct 1, 1995·Anesthesia and Analgesia·J G StoneJ Diaz
Jul 1, 1995·Clinical Pharmacology and Therapeutics·N R CutlerE P Brass

❮ Previous
Next ❯

Citations

Oct 7, 2003·European Journal of Drug Metabolism and Pharmacokinetics·A FuruyaH Ogata
Sep 24, 2002·Toxicology Letters·Jim E RiviereRonald E Baynes
Jul 23, 2005·International Journal of Toxicology·G A PetroianuM Y Hasan
Mar 8, 2005·Drug Metabolism Reviews·Ernest Hodgson, Randy L Rose
Jan 10, 2002·Journal of Pharmaceutical Sciences·Bernd Meibohm, Hartmut Derendorf
Aug 4, 2009·Toxicology and Applied Pharmacology·Corey J HilmasPatrick T Williams
Jun 25, 2002·Toxicology and Applied Pharmacology·Ronald E BaynesJim E Riviere
Oct 31, 2002·Human Psychopharmacology·Alain Patat
Oct 31, 2001·Alimentary Pharmacology & Therapeutics·R De GiorgioF De Ponti
Oct 8, 2019·Journal of Neurogastroenterology and Motility·Giovanni Di NardoRoberto De Giorgio
Mar 26, 2003·Journal of Toxicology and Environmental Health. Part a·Jim E RiviereNancy A Monteiro-Riviere
Feb 27, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Thomas A DewlandStuart D Katz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.